M. W. Peck, T. J. Smith, F. Anniballi, J. W. Austin, L. Bano et al., Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature, Toxins, vol.9, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01821691

J. Sobel and . Botulism, Clin. Infect. Dis, vol.41, pp.1167-1173, 2005.

I. Brook, Botulism symptoms, incubation period and complications, diagnosis and management. In Clostridium Botulinum: A Spore Forming Organism and a Challenge to Food Safety; Advances in Food Safety and Food Microbiology, 2012.

C. O. Gill and N. Penney, The occurrence of clostridium botulinum at aquatic sites in and around auckland and other urban areas of the North Island, N. Z. Vet. J, vol.30, pp.110-112, 1982.

D. M. Gill, Bacterial toxins: A table of lethal amounts, Microbiol. Rev, vol.46, pp.86-94, 1982.

A. Fischer, C. Garcia-rodriguez, I. Geren, J. Lou, J. D. Marks et al., Molecular architecture of botulinum neurotoxin e revealed by single particle electron microscopy, J. Biol. Chem, vol.283, pp.3997-4003, 2008.

S. S. Arnon, R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett et al., Botulinum toxin as a biological weapon: Medical and public health management, JAMA, vol.285, pp.1059-1070, 2001.

G. Bozheyeva, Y. Kunakbayev, and D. Yeleukenov, Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present, and Future; Monterey Institute of International Studies, 1999.

L. M. Wein and Y. Liu, Analyzing a bioterror attack on the food supply: The case of botulinum toxin in milk, Proc. Natl. Acad. Sci, vol.102, pp.9984-9989, 2005.

K. Jalava, K. Selby, A. Pihlajasaari, E. Kolho, E. Dahlsten et al., Two cases of food-borne botulism in Finland caused by conserved olives, vol.16, 2011.

J. A. Coffield, N. Bakry, R. D. Zhang, J. Carlson, L. G. Gomella et al., In vitro characterization of botulinum toxin types A, C and D action on human tissues: Combined electrophysiologic, pharmacologic and molecular biologic approaches, J. Pharmacol. Exp. Ther, vol.280, pp.1489-1498, 1997.

A. L. Halpin, J. M. Khouri, J. R. Payne, J. H. Nakao, A. Cronquist et al., Type F infant botulism: Investigation of recent clusters and overview of this exceedingly rare disease, Clin. Infect. Dis, vol.66, pp.92-94, 2017.

J. R. Barash and S. S. Arnon, A novel strain of clostridium botulinum that produces type b and type h botulinum toxins, J. Infect. Dis, vol.209, pp.183-191, 2014.

S. E. Maslanka, C. Luquez, J. K. Dykes, W. H. Tepp, C. L. Pier et al., A novel botulinum neurotoxin, previously reported as serotype h, has a hybrid-like structure with regions of similarity to the structures of serotypes a and f and is neutralized with serotype a antitoxin, J. Infect. Dis, vol.213, pp.379-385, 2016.

E. A. Johnson, Validity of botulinum neurotoxin serotype h, J. Infect. Dis, vol.210, pp.992-993, 2014.

M. J. Mansfield, J. B. Adams, and A. C. Doxey, Botulinum neurotoxin homologs in non-clostridium species, FEBS Lett, vol.589, pp.342-348, 2015.

S. Zhang, G. Masuyer, J. Zhang, Y. Shen, D. Lundin et al., Identification and characterization of a novel botulinum neurotoxin, Nat. Commun, vol.8, 2017.

I. Zornetta, D. Azarnia-tehran, G. Arrigoni, F. Anniballi, L. Bano et al., The first non clostridial botulinum-like toxin cleaves vamp within the juxtamembrane domain, Sci. Rep, vol.6, 2016.

S. Kosenina, G. Masuyer, S. Zhang, M. Dong, and P. Stenmark, Crystal structure of the catalytic domain of the weissella oryzae botulinum-like toxin, FEBS Lett, vol.593, pp.1403-1410, 2019.

J. Brunt, A. T. Carter, S. C. Stringer, and M. W. Peck, Identification of a novel botulinum neurotoxin gene cluster in enterococcus, FEBS Lett, vol.592, pp.310-317, 2018.

D. B. Lacy, W. Tepp, A. C. Cohen, B. R. Dasgupta, and R. C. Stevens, Crystal structure of botulinum neurotoxin type a and implications for toxicity, Nat. Struct. Biol, vol.5, pp.898-902, 1998.

D. Kumaran, S. Eswaramoorthy, W. Furey, J. Navaza, M. Sax et al., Domain organization in clostridium botulinum neurotoxin type e is unique: Its implication in faster translocation, J. Mol. Biol, vol.386, pp.233-245, 2009.

C. Montecucco and G. Schiavo, Structure and function of tetanus and botulinum neurotoxins, Q. Rev. Biophys, vol.28, pp.423-472, 1995.

M. Montal, Botulinum neurotoxin: A marvel of protein design, Annu. Rev. Biochem, vol.79, pp.591-617, 2010.

C. Verderio, O. Rossetto, C. Grumelli, C. Frassoni, C. Montecucco et al., Entering neurons: Botulinum toxins and synaptic vesicle recycling, EMBO Rep, vol.7, pp.995-999, 2006.

O. Rossetto, F. Deloye, B. Poulain, R. Pellizzari, G. Schiavo et al., The metallo-proteinase activity of tetanus and botulism neurotoxins, J. Physiol, vol.89, pp.43-50, 1995.

M. Pirazzini, O. Rossetto, R. Eleopra, and C. Montecucco, Botulinum neurotoxins: Biology, pharmacology, and toxicology, Pharm. Rev, vol.69, pp.200-235, 2017.

T. Matsumura, Y. Jin, Y. Kabumoto, Y. Takegahara, K. Oguma et al., The ha proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption, Cell. Microbiol, vol.10, pp.355-364, 2008.

Y. Sugawara, T. Matsumura, Y. Takegahara, Y. Jin, Y. Tsukasaki et al., Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding e-cadherin, J. Cell Biol, vol.189, pp.691-700, 2010.

T. Matsumura, Y. Sugawara, M. Yutani, S. Amatsu, H. Yagita et al., Botulinum toxin a complex exploits intestinal m cells to enter the host and exert neurotoxicity, Nat. Commun, vol.6, p.6255, 2015.

C. Connan, C. Varela-chavez, C. Mazuet, J. Molgo, G. M. Haustant et al., Translocation and dissemination to target neurons of botulinum neurotoxin type b in the mouse intestinal wall, Cell. Microbiol, vol.18, pp.282-301, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-01780625

M. Pirazzini and O. Rossetto, Challenges in searching for therapeutics against botulinum neurotoxins, Expert Opin. Drug Discov, vol.12, pp.497-510, 2017.

J. M. Khouri, R. N. Motter, and S. S. Arnon, Safety and immunogenicity of investigational recombinant botulinum vaccine, rbv a/b, in volunteers with pre-existing botulinum toxoid immunity, vol.36, pp.2041-2048, 2018.

S. S. Arnon, R. Schechter, S. E. Maslanka, N. P. Jewell, and C. L. Hatheway, Human botulism immune globulin for the treatment of infant botulism, N. Engl. J. Med, vol.354, pp.462-471, 2006.

R. P. Fagan, K. P. Neil, R. Sasich, C. Luquez, H. Asaad et al., Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin, Clin. Infect. Dis, vol.53, pp.125-128, 2011.

J. M. Rusnak and L. A. Smith, Botulinum neurotoxin vaccines: Past history and recent developments, vol.5, pp.794-805, 2009.

M. A. Fiock, M. A. Cardella, and N. F. Gearinger, Studies on immunity to toxins of clostridium botulinum. Ix. Immunologic response of man to purified pentavalent abcde botulinum toxiod, J. Immunol, vol.90, pp.697-702, 1963.

M. P. Byrne and L. A. Smith, Development of vaccines for prevention of botulism, Biochimie, vol.82, pp.955-966, 2000.

L. S. Siegel, Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (abcde) toxoid, J. Clin. Microbiol, vol.27, pp.1906-1908, 1989.

J. E. Keller, Characterization of new formalin-detoxified botulinum neurotoxin toxoids, Clin. Vaccine Immunol, vol.15, pp.1374-1379, 2008.

D. Li, P. Mattoo, and J. E. Keller, New equine antitoxins to botulinum neurotoxins serotypes a and b, Biologicals, vol.40, pp.240-246, 2012.

K. Mottate, H. Yokote, S. Mori, A. Horita, Y. Miyatsu et al., Retrospective survey to evaluate the safety and efficacy of japanese botulinum antitoxin therapy in japan, Toxicon, vol.110, pp.12-18, 2016.

, CDC. Investigational heptavalent botulinum antitoxin (hbat) to replace licensed botulinum antitoxin ab and investigational botulinum antitoxin E. Mmwr, p.299, 2010.

J. Moneim, Question 1: In infant botulism, is equine-derived botulinum antitoxin (eqba) an effective alternative therapy to human-derived botulinum immune globulin (big)?, Arch. Dis. Child, vol.103, pp.907-909, 2018.

T. J. Smith, J. Lou, I. N. Geren, C. M. Forsyth, R. Tsai et al., Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization, Infect. Immun, vol.73, pp.5450-5457, 2005.

C. Rasetti-escargueil, A. Avril, S. Miethe, C. Mazuet, Y. Derman et al., The european antibotabe framework program and its update: Development of innovative botulinum antibodies, Toxins, vol.9, 2017.

A. Avril, J. W. Froude, J. Mathieu, T. Pelat, and P. Thullier, Isolation of antibodies from non-human primates for clinical use, Curr. Drug Discov. Technol, vol.11, pp.20-27, 2014.

T. Pelat and P. Thullier, Non-human primate immune libraries combined with germline humanization: An (almost) new, and powerful approach for the isolation of therapeutic antibodies, MAbs, vol.1, pp.377-381, 2009.

F. Chen, G. M. Kuziemko, P. Amersdorfer, C. Wong, J. D. Marks et al., Antibody mapping to domains of botulinum neurotoxin serotype a in the complexed and uncomplexed forms, Infect. Immun, vol.65, pp.1626-1630, 1997.

R. Levy, C. M. Forsyth, S. L. Laporte, I. N. Geren, L. A. Smith et al., Fine and domain-level epitope mapping of botulinum neurotoxin type a neutralizing antibodies by yeast surface display, J. Mol. Biol, vol.365, pp.196-210, 2007.

B. P. Mullaney, M. G. Pallavicini, and J. D. Marks, Epitope mapping of neutralizing botulinum neurotoxin a antibodies by phage display, Infect. Immun, vol.69, pp.6511-6514, 2001.

M. Z. Atassi and B. Z. Dolimbek, Mapping of the antibody-binding regions on the hn-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the h-chain of botulinum neurotoxin A, Protein J, vol.23, pp.39-52, 2004.

M. Z. Atassi, G. S. Dolimbek, P. R. Deitiker, K. R. Aoki, and B. Z. Dolimbek, Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A, Mol. Immunol, vol.42, pp.1509-1520, 2005.

M. T. Dertzbaugh and M. W. West, Mapping of protective and cross-reactive domains of the type a neurotoxin of clostridium botulinum, vol.14, pp.1538-1544, 1996.

Y. Espinoza, D. Wong, A. Ahene, K. Der, Z. Martinez et al., Pharmacokinetics of human recombinant anti-botulinum toxin antibodies in rats. Toxins (Basel) 2019, vol.11

J. Sepulveda, J. Mukherjee, S. Tzipori, L. L. Simpson, and C. B. Shoemaker, Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents, Infect. Immun, vol.78, pp.756-763, 2010.

S. P. Adekar, F. H. Al-saleem, M. D. Elias, K. A. Rybinski, L. L. Simpson et al., A natural human igm antibody that neutralizes botulinum neurotoxin in vivo, Hybridoma (Larchmt), vol.27, pp.65-69, 2008.

S. P. Adekar, R. M. Jones, M. D. Elias, F. H. Al-saleem, M. J. Root et al., Hybridoma populations enriched for affinity-matured human iggs yield high-affinity antibodies specific for botulinum neurotoxins, J. Immunol. Methods, vol.333, pp.156-166, 2008.

M. Z. Atassi, B. Z. Dolimbek, J. Jankovic, L. E. Steward, and K. R. Aoki, Molecular recognition of botulinum neurotoxin b heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment, Mol. Immunol, vol.45, pp.3878-3888, 2008.

B. Z. Dolimbek, L. E. Steward, K. R. Aoki, and M. Z. Atassi, Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin a: Antigenic structure of the entire toxin, Immunobiology, vol.216, pp.698-706, 2011.

M. Z. Atassi, Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions, Toxicon, vol.107, pp.50-58, 2015.

J. D. Marks, Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization, Mov. Disord, vol.19, pp.101-108, 2004.

C. Mazuet, J. Dano, M. R. Popoff, C. Creminon, and H. Volland, Characterization of botulinum neurotoxin type a neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity, PLoS ONE, vol.5, 2010.
URL : https://hal.archives-ouvertes.fr/pasteur-01762095

A. Nowakowski, C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith et al., Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, Proc. Natl. Acad. Sci, vol.99, pp.11346-11350, 2002.

Y. Fan, J. Dong, J. Lou, W. Wen, F. Conrad et al., Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype/b. Toxins (Basel), vol.7, pp.3405-3423, 2015.

Y. Fan, C. Garcia-rodriguez, J. Lou, W. Wen, F. Conrad et al., A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype f subtypes, PLoS ONE, vol.12, 2017.

Y. Fan, I. N. Geren, J. Dong, J. Lou, W. Wen et al., Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/a inhibit catalytic activity, PLoS ONE, vol.10, 2015.

C. Garcia-rodriguez, I. N. Geren, J. Lou, F. Conrad, C. Forsyth et al., Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin, Protein Eng. Des. Sel, vol.24, pp.321-331, 2011.

C. Garcia-rodriguez, A. Razai, I. N. Geren, J. Lou, F. Conrad et al., A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype e subtypes, Toxins (Basel, issue.10, p.105, 2018.

E. Diamant, B. E. Lachmi, A. Keren, A. Barnea, H. Marcus et al., Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations, PLoS ONE, vol.9, p.87089, 2014.

S. G. Abbasova, N. V. Ruddenko, A. Gorokhovatskii, M. V. Kapralova, I. D. Vinogradova et al., Monoclonal antibodies to type a, b, e and f botulinum neurotoxins, Russ. J. Bioorganic Chem, vol.37, pp.344-353, 2011.

J. Mukherjee, C. Mccann, K. Ofori, J. Hill, K. Baldwin et al., Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin a1, Toxins (Basel), vol.2012, pp.1565-1581

S. R. Kalb, W. I. Santana, I. N. Geren, C. Garcia-rodriguez, J. Lou et al., Extraction and inhibition of enzymatic activity of botulinum neurotoxins /b1, /b2, /b3, /b4, and /b5 by a panel of monoclonal anti-bont/b antibodies, BMC Biochem, vol.12, 2011.

C. Chen, S. Wang, H. Wang, X. Mao, T. Zhang et al., Potent neutralization of botulinum neurotoxin/b by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain, PLoS ONE, vol.7, 2012.

M. T. Tomic, Y. Espinoza, Z. Martinez, K. Pham, R. R. Cobb et al., Monoclonal antibody combinations prevent serotype a and serotype b inhalational botulism in a guinea pig model, Toxins

M. Mukamoto, H. Maeda, T. Kohda, C. Nozaki, M. Takahashi et al., Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A, Microbiol. Immunol, vol.56, pp.748-755, 2012.

M. Mukamoto, H. Maeda, T. Kohda, C. Nozaki, M. Takahashi et al., Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E, Jpn. J. Infect. Dis, vol.66, pp.46-50, 2013.

J. Prigent, C. Mazuet, D. Boquet, P. Lamourette, H. Volland et al., Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A, PLoS ONE, vol.5, 2010.
URL : https://hal.archives-ouvertes.fr/pasteur-01762123

T. Takahashi, S. G. Joshi, F. Al-saleem, D. Ancharski, A. Singh et al., Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin, vol.27, pp.2616-2624, 2009.

L. W. Cheng, L. H. Stanker, T. D. Henderson, J. Lou, and J. D. Marks, Antibody protection against botulinum neurotoxin intoxication in mice, Infect. Immun, vol.77, pp.4305-4313, 2009.

R. Sharma, H. Zhao, F. H. Al-saleem, A. S. Ubaid, R. D. Puligedda et al., Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor, Mol. Immunol, vol.57, pp.247-254, 2014.

F. H. Al-saleem, R. Sharma, R. D. Puligedda, M. Elias, C. D. Kattala et al., Rbc adherence of immune complexes containing botulinum toxin improves neutralization and macrophage uptake, Toxins, vol.9, p.173, 2017.

S. P. Adekar, A. T. Segan, C. Chen, R. Bermudez, M. D. Elias et al., Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein, PLoS ONE, vol.6, 2011.

S. P. Adekar, T. Takahashi, R. M. Jones, F. H. Al-saleem, D. M. Ancharski et al., Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain, PLoS ONE, vol.3, 2008.

F. H. Al-saleem, Z. Nasser, R. M. Olson, L. Cao, and L. L. Simpson, Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: A model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare, J. Pharmacol. Exp. Ther, vol.338, pp.503-517, 2011.

. Shoemaker, Design options for mrna-encoded bont antitoxins employing camelid single-domain antibody (vhh) components, Toxicon, vol.156, p.120, 2018.

B. V. Ayyar, R. B. Tajhya, C. Beeton, and M. Z. Atassi, Antigenic sites on the hn domain of botulinum neurotoxin a stimulate protective antibody responses against active toxin, Sci. Rep, vol.5, 2015.

J. Strotmeier, S. Mahrhold, N. Krez, C. Janzen, J. Lou et al., Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A, FEBS Lett, vol.588, pp.1087-1093, 2014.

M. Tavallaie, A. Chenal, D. Gillet, Y. Pereira, M. Manich et al., Interaction between the two subdomains of the c-terminal part of the botulinum neurotoxin a is essential for the generation of protective antibodies, FEBS Lett, vol.572, pp.299-306, 2004.

D. J. Barrera, J. N. Rosenberg, J. G. Chiu, Y. N. Chang, M. Debatis et al., Algal chloroplast produced camelid vh h antitoxins are capable of neutralizing botulinum neurotoxin, Plant. Biotechnol. J, vol.13, pp.117-124, 2015.

R. Baghban, S. L. Gargari, M. Rajabibazl, S. Nazarian, and H. Bakherad, Camelid-derived heavy-chain nanobody against clostridium botulinum neurotoxin E in pichia pastoris, Biotechnol. Appl. Biochem, vol.63, pp.200-205, 2016.

J. M. Tremblay, C. L. Kuo, C. Abeijon, J. Sepulveda, G. Oyler et al., Camelid single domain antibodies (vhhs) as neuronal cell intrabody binding agents and inhibitors of clostridium botulinum neurotoxin (bont) proteases, Toxicon, vol.56, pp.990-998, 2010.

N. J. Huang, N. Pishesha, J. Mukherjee, S. Zhang, R. Deshycka et al., Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin, Nat. Commun, vol.8, p.423, 2017.

C. Trollet, Y. Pereira, A. Burgain, E. Litzler, M. Mezrahi et al., Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer, Infect. Immun, vol.77, pp.2221-2229, 2009.

D. L. Trott, M. Yang, J. Gonzalez, A. E. Larson, W. H. Tepp et al., Egg yolk antibodies for detection and neutralization of clostridium botulinum type A neurotoxin, J. Food Prot, vol.72, pp.1005-1011, 2009.

A. Burgain, A. Rochard, C. Trollet, C. Mazuet, M. R. Popoff et al., DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: Examples of the botulinum toxins types A, B, and E, Hum. Vaccin Immunother, vol.9, pp.2147-2156, 2013.

P. Amersdorfer and J. D. Marks, Phage libraries for generation of anti-botulinum scfv antibodies, Methods Mol. Biol, vol.145, pp.219-240, 2000.

P. Amersdorfer, C. Wong, S. Chen, T. Smith, S. Deshpande et al., Molecular characterization of murine humoral immune response to botulinum neurotoxin type a binding domain as assessed by using phage antibody libraries, Infect. Immun, vol.65, pp.3743-3752, 1997.

P. Amersdorfer, C. Wong, T. Smith, S. Chen, S. Deshpande et al., Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries, vol.20, pp.1640-1648, 2002.

H. C. Wu, C. T. Yeh, Y. L. Huang, L. J. Tarn, and C. C. Lung, Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the clostridium botulinum neurotoxin type A, Appl. Environ. Microbiol, vol.67, pp.3201-3207, 2001.

H. Zhou, B. Zhou, S. Pellett, E. A. Johnson, and K. D. Janda, Selection and characterization of a human monoclonal neutralizing antibody for clostridium botulinum neurotoxin serotype B, Bioorganic Med. Chem. Lett, vol.19, pp.662-664, 2009.

R. Yu, S. Wang, Y. Z. Yu, W. S. Du, F. Yang et al., Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library, J. Biomol. Screen, vol.14, pp.991-998, 2009.

J. Lou, I. Geren, C. Garcia-rodriguez, C. M. Forsyth, W. Wen et al., Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating, Protein Eng. Des. Sel, vol.23, pp.311-319, 2010.

H. Bakherad, S. L. Mousavi-gargari, I. Rasooli, M. Rajabibazl, M. Mohammadi et al., In vivo neutralization of botulinum neurotoxins serotype e with heavy-chain camelid antibodies (vhh), Mol. Biotechnol, vol.55, pp.159-167, 2013.

Y. Fan, J. R. Barash, J. Lou, F. Conrad, J. D. Marks et al., Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H, J. Infect. Dis, vol.213, pp.1606-1614, 2016.

S. Pellett, W. H. Tepp, M. Bradshaw, S. R. Kalb, J. K. Dykes et al., Purification and characterization of botulinum neurotoxin fa from a genetically modified clostridium botulinum strain, vol.1, 2016.

M. Li, D. Lee, C. R. Obi, J. K. Freeberg, S. Farr-jones et al., An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E, PLoS ONE, vol.13, 2018.

S. U. Nayak, J. M. Griffiss, R. Mckenzie, E. J. Fuchs, R. A. Jurao et al., Safety and pharmacokinetics of xoma 3ab, a novel mixture of three monoclonal antibodies against botulinum toxin A, Antimicrob. Agents Chemother, vol.58, pp.5047-5053, 2014.

L. A. Smith, Botulism and vaccines for its prevention, Vaccine, vol.27, pp.33-39, 2009.

R. Kaji, New and emerging indications of botulinum toxin therapy, Parkinsonism Relat. Disord, vol.17, pp.25-27, 2011.

E. Fonfria, J. Maignel, S. Lezmi, V. Martin, A. Splevins et al., The expanding therapeutic utility of botulinum neurotoxins, Toxins (Basel, vol.10, 2018.

J. Jankovic, An update on new and unique uses of botulinum toxin in movement disorders, Toxicon, vol.147, pp.84-88, 2018.

J. O. Dolly, G. W. Lawrence, J. Meng, J. Wang, S. V. Ovsepian et al., Botulinum toxins as inhibitory probes and versatile therapeutics, vol.9, pp.326-335, 2009.

D. Dressler, Clinical applications of botulinum toxin, Curr. Opin. Microbiol, vol.15, pp.325-336, 2012.

D. Dressler and P. Roggenkaemper, A brief history of neurological botulinum toxin therapy in germany, J. Neural Transm, vol.124, pp.1217-1221

M. F. Brin, K. Tan, and C. Gallagher, Differences in botulinum toxins: Time to end the confusion, J. Cosmet. Laser Ther, vol.11, pp.180-181, 2009.

M. A. Wollmer, C. De-boer, N. Kalak, J. Beck, T. Gotz et al., Facing depression with botulinum toxin: A randomized controlled trial, J. Psychiatr. Res, vol.46, pp.574-581, 2012.

H. Dong, S. Fan, Y. Luo, and B. Peng, Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm, Neuropsychiatr. Dis. Treat, vol.15, pp.33-36, 2019.

A. Przedpelski, W. H. Tepp, M. Zuverink, E. A. Johnson, S. Pellet et al., Enhancing toxin-based vaccines against botulism, vol.36, pp.827-832, 2018.

W. Mustafa, F. H. Al-saleem, Z. Nasser, R. M. Olson, J. A. Mattis et al., Immunization of mice with the non-toxic hc50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge, vol.29, pp.4638-4645, 2011.

R. Zichel, A. Mimran, A. Keren, A. Barnea, I. Steinberger-levy et al., Efficacy of a potential trivalent vaccine based on hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system, Clin. Vaccine Immunol, vol.17, pp.784-792, 2010.

Y. Z. Yu, J. P. Guo, H. J. An, S. M. Zhang, S. Wang et al., Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based semliki forest virus replicon vectors, vol.31, pp.2427-2432, 2013.

Y. Z. Yu, S. Liu, Y. Ma, Z. W. Gong, S. Wang et al., Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based semliki forest virus replicon vectors, Hum. Vaccin Immunother, vol.10, pp.1874-1879, 2014.

J. D. Shearer, M. L. Vassar, W. Swiderski, K. Metcalfe, N. Niemuth et al., Botulinum neurotoxin neutralizing activity of immune globulin (ig) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rbv a/b). Vaccine, vol.28, pp.7313-7318, 2010.

V. L. Scott, D. O. Villarreal, N. A. Hutnick, J. N. Walters, E. Ragwan et al., DNA vaccines targeting heavy chain c-terminal fragments of clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge, Hum. Vaccin Immunother, vol.11, 1961.

J. Zeng, J. Du, Y. Zhao, N. Palanisamy, and S. Wang, Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells, Stem Cells, vol.25, pp.1055-1061, 2007.

D. M. White, S. Pellett, M. A. Jensen, W. H. Tepp, E. A. Johnson et al., Rapid immune responses to a botulinum neurotoxin hc subunit vaccine through in vivo targeting to antigen-presenting cells, Infect. Immun, vol.79, pp.3388-3396, 2011.

S. Jun, B. Clapp, D. Zlotkowska, T. Hoyt, K. Holderness et al., Sublingual immunization with adenovirus f protein-based vaccines stimulates protective immunity against botulinum neurotoxin a intoxication, Int. Immunol, vol.24, pp.117-128, 2012.

Y. Torii, N. Sugimoto, T. Kohda, S. Kozaki, K. Morokuma et al., Clinical study of new tetravalent (type A, B, E, and F) botulinum toxoid vaccine derived from m toxin in japan, Jpn. J. Infect. Dis, vol.70, pp.423-429, 2017.

R. P. Webb, T. J. Smith, L. A. Smith, P. M. Wright, R. L. Guernieri et al., Recombinant botulinum neurotoxin hc subunit (bont hc) and catalytically inactive clostridium botulinum holoproteins (cibont hps) as vaccine candidates for the prevention of botulism, Toxins, vol.9, p.269, 2017.

C. H. Yu, D. H. Song, J. Y. Choi, H. E. Joe, W. H. Jeong et al., A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication, Hum. Vaccin Immunother, vol.14, pp.329-336, 2018.

H. C. Chen, C. I. Yen, S. Y. Yang, C. J. Chang, J. Y. Yang et al., Reply: Comparison of steroid and botulinum toxin type a monotherapy with combination therapy for treating human hypertrophic scars in an animal model, Plast. Reconstr. Surg, vol.141, pp.452-453, 2018.